Feifei Teng, MD, PhD

Shandong Anti-Cancer Association
Jinan, Shandong

Disclosures:

• Employment: none
• Compensation: :Role Topic Description-End Date:
• Ownership: none
• Leadership: none

Presentation(s):

• 2153 - CRUISER: A Phase 2 Trial of Concurrent durvalumab with Chemoradiation Therapy Followed by durvalumab in Chinese Unresectable Stage III Non-Small Cell Lung Cancer Patients

  Sunday, September 29, 2024
  2:45 PM – 4:15 PM ET

• 2154 - Noninvasive Radiomic Biomarkers for Predicting Pseudoprogression and Hyperprogression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

  Sunday, September 29, 2024
  2:45 PM – 4:15 PM ET

• 2155 - CT-Based Radiomics and Genomics Analysis for Survival Prediction in Stage III Unresectable Non-Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy Following with Immunotherapy

  Sunday, September 29, 2024
  2:45 PM – 4:15 PM ET

• 2891 - Loss of Tumor Intrinsic RIPK1, Antitumor Immune Responses, and the Efficacy of PD-1 Blockade

  Monday, September 30, 2024
  5:00 PM – 6:00 PM ET

• 268 - The Role of RIPK1 in Mediating Enhanced Immune Responses Following Radiotherapy

  Tuesday, October 1, 2024
  1:35 PM – 1:45 PM ET